Maze Therapeutics, Inc. (MAZE)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGM
26.84 USD
-1.25
(-4.450%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:58 p.m. EDT
Despite overwhelming positive Phase 2 data and biotech analyst upgrades, the stock is trapped in a 'value trap' due to a 30-35% retracement that has decoupled the asset from its clinical potential. Sellers are currently in control, evidenced by the heavy put positioning and insider selling (CMO liquidation), suggesting speculators have priced in a continued grind to the downside rather than an immediate recovery to multi-month highs. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.175332 |
| AutoETS | 0.175400 |
| MSTL | 0.178217 |
| AutoTheta | 0.225074 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 137.71 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.027 |
| Excess Kurtosis | -1.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 6.566 |
| Market Cap | 1,334,180,352 |
| Forward P/E | -7.70 |
| Website | https://www.mazetx.com |
As of April 18, 2026, 11:58 p.m. EDT: Options flow is heavily skewed bearish in the near term, with massive open interest concentration in ITM puts ($40k, $30k strikes) compared to negligible call OI beyond ATM. The $40k call spread shows significant speculative 'lottery ticket' positioning, likely representing contrarian bets on a reversal to par levels, but the dominant market structure is defensive. The extremely low OTM put % (0.01% for May) versus high OTM call % (99%) indicates a market consensus pricing in further downside risk rather than an imminent catalyst-driven rally, despite the high implied volatility anchor.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.7221096 |
| Address1 | 171 Oyster Point Blvd |
| Address2 | Suite 300 |
| All Time High | 53.65 |
| All Time Low | 6.71 |
| Ask | 34.34 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,031,840 |
| Average Daily Volume3 Month | 838,575 |
| Average Volume | 838,575 |
| Average Volume10Days | 1,031,840 |
| Bid | 20.02 |
| Bid Size | 2 |
| Book Value | 7.196 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 26.84 |
| Current Ratio | 15.504 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 28.53 |
| Day Low | 26.795 |
| Debt To Equity | 6.566 |
| Display Name | Maze Therapeutics |
| Earnings Timestamp | 1,774,441,800 |
| Earnings Timestamp End | 1,778,070,600 |
| Earnings Timestamp Start | 1,778,070,600 |
| Ebitda | -140,496,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.228 |
| Enterprise Value | 1,015,569,408 |
| Eps Current Year | -2.7816 |
| Eps Forward | -3.48406 |
| Eps Trailing Twelve Months | -3.05 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 40.539 |
| Fifty Day Average Change | -13.699001 |
| Fifty Day Average Change Percent | -0.33792153 |
| Fifty Two Week Change Percent | 172.21095 |
| Fifty Two Week High | 53.65 |
| Fifty Two Week High Change | -26.810001 |
| Fifty Two Week High Change Percent | -0.49972042 |
| Fifty Two Week Low | 7.16 |
| Fifty Two Week Low Change | 19.68 |
| Fifty Two Week Low Change Percent | 2.7486033 |
| Fifty Two Week Range | 7.16 - 53.65 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,738,333,800,000 |
| Float Shares | 27,698,658 |
| Forward Eps | -3.48406 |
| Forward P E | -7.703656 |
| Free Cashflow | -72,523,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 141 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01821 |
| Held Percent Institutions | 1.0307599 |
| Implied Shares Outstanding | 49,708,658 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-01-31 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California. |
| Long Name | Maze Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,334,180,352 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_602685968 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -131,120,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,334,180,380 |
| Number Of Analyst Opinions | 11 |
| Open | 28.05 |
| Operating Cashflow | -111,940,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 850 5070 |
| Pre Market Change | 0.27000046 |
| Pre Market Change Percent | 1.005963 |
| Pre Market Price | 27.11 |
| Pre Market Time | 1,776,772,862 |
| Previous Close | 28.09 |
| Price Eps Current Year | -9.649123 |
| Price Hint | 2 |
| Price To Book | 3.7298498 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.225 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.08333 |
| Region | US |
| Regular Market Change | -1.25 |
| Regular Market Change Percent | -4.44998 |
| Regular Market Day High | 28.53 |
| Regular Market Day Low | 26.795 |
| Regular Market Day Range | 26.795 - 28.53 |
| Regular Market Open | 28.05 |
| Regular Market Previous Close | 28.09 |
| Regular Market Price | 26.84 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 527,269 |
| Return On Assets | -0.28012 |
| Return On Equity | -0.47518003 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 49,708,658 |
| Shares Percent Shares Out | 0.0783 |
| Shares Short | 3,890,308 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,438,552 |
| Short Name | Maze Therapeutics, Inc. |
| Short Percent Of Float | 0.0932 |
| Short Ratio | 3.35 |
| Source Interval | 15 |
| State | CA |
| Symbol | MAZE |
| Target High Price | 110.0 |
| Target Low Price | 46.0 |
| Target Mean Price | 64.45455 |
| Target Median Price | 58.0 |
| Total Cash | 341,916,992 |
| Total Cash Per Share | 6.878 |
| Total Debt | 23,306,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.05 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 31.5505 |
| Two Hundred Day Average Change | -4.7105007 |
| Two Hundred Day Average Change Percent | -0.14930035 |
| Type Disp | Equity |
| Volume | 527,269 |
| Website | https://www.mazetx.com |
| Zip | 94,080 |